Enzyme inhibitors for carcinoid syndrome (Formulary)

Important: Formulation and dosage details

Formulation:

Tablets 250mg (specialist initiation only)

Dosage:

As per SMC 1327/18: Treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue therapy in adults inadequately controlled by somatostatin analogue therapy.
SMC restriction: patients with CS diarrhoea who experience an average of four or more bowel motions per day, despite receiving somatostatin analogue therapy.